Usually, a clinician is reliant on the timing of symptom onset and progression of the disease to differentiate these, for example, A-CIDP should be suspected when the symptoms relapse and remit or progress for more than 2 months or occur more than three times (9) and GBS-TRF has one or two post-treatment deteriorations, most within 9 weeks from onset, and has a more rapid onset of weakness. This evidence concerns the gene PMP22 and Guillain-Barre syndrome.